The prevalence of metabolic syndrome and its association with alanine aminotransferase in clozapine-treated Korean patients with schizophrenia

International Clinical Psychopharmacology

Volumn 28, Issue 2, 2013, Pages 71-79

  Lee, N Y ^a,b   Roh, M S ^c   Kim, S H ^c   Jung, D C ^d   Yu, H Y ^d   Sung, K H ^e   Chung, I W ^a,b   Youn, T ^a,b   Kang, U G ^c,d   Ahn, Y M ^c,d   Kim, Y S ^a,b,c  

^a Dongguk University Ilsan Hospital   (South Korea)

^b Dongguk University College of Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e Ewha Womans University   (South Korea)

Author keywords

alanine aminotransferase; clozapine; indirectly standardized prevalence ratio; metabolic syndrome; schizophrenia

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CLOZAPINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH SURVEY; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; WAIST CIRCUMFERENCE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ALANINE TRANSAMINASE; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; CLOZAPINE; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK; SCHIZOPHRENIA; SEX CHARACTERISTICS; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 84873412518     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32835b99bd     Document Type: Article

References (56)

1. Ahmed M, Hussain I, O'Brien SM, Dineen B, Griffin D, McDonald C (2008). Prevalence and associations of the metabolic syndrome among patients prescribed clozapine. Ir J Med Sci 177:205-210.
2. Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. (2009). Harmonizing the metabolic syndrome. Circulation 120:1640-1645.
3. Alberti KG, Zimmet P, Shaw J (2006). Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabetic Medicine: a Journal of the British Diabetic Association 23: 469-480.
4. Atasoy N, Erdogan A, Yalug I, Ozturk U, Konuk N, Atik L, et al. (2007). A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study. Prog Neuropsychopharmacol Biol Psychiatry 31:1255-1260.
5. Bai YM, Lin CC, Chen JY, Chen TT, Su TP, Chou P (2011). Association of weight gain and metabolic syndrome in patients taking clozapine: an 8-year cohort study. J Clin Psychiatry 72:751-756.
6. Baik I (2009). Optimal cutoff points of waist circumference for the criteria of abdominal obesity: comparison with the criteria of the International Diabetes Federation. Circulation Journal: Official Journal of the Japanese Circulation Society 73:2068-2075.
7. Bhuvaneswar CG, Baldessarini RJ, Harsh VL, Alpert JE (2009). Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. CNS Drugs 23:1003-1021.
8. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J (2007). Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 90 (1-3):162-173.
9. Boden R, Haenni A, Lindstrom L, Sundstrom J (2009). Biochemical risk factors for development of obesity in first-episode schizophrenia. Schizophr Res 115 (2-3):141-145.
10. Boyda HN, Tse L, Procyshyn RM, Honer WG, Barr AM (2010). Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol Sci 31:484-4497.
11. Cerit C, Vural M, Bos GSU, Ozten E, Aker A, Yildiz M (2010). Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study. Psycho-pharmacol Bull 43:22-36.
12. Chokka P, Tancer M, Yeragani VK (2006). Metabolic syndrome: relevance to antidepressant treatment. J Psychiatry Neurosci 31:414.
13. Chuang SY, Chen CH, Chou P (2004). Prevalence of metabolic syndrome in a large health check-up population in Taiwan. J Chin Med Assoc 67:611-620.
14. Citrome L, Krakowski M (2009). The impact of ethnicity on metabolic outcomes during treatment with antipsychotics: complexities abound. J Clin Psychiatry 70:1608-1609.
15. De Hert M, Van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. (2006). Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clinical Practice and Epidemiology in Mental Health 2:14.
16. De Hert M, Schreurs V, Vancampfort D, Van Winkel R (2009). Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 8: 15-22.
17. Eckel RH, Alberti K, Grundy SM, Zimmet PZ (2010). The metabolic syndrome. Lancet 375:181-183.
18. Goessling W, Massaro JM, Vasan RS, D'Agostino RB Sr, Ellison RC, Fox CS (2008). Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 135:1935-1944.
19. Grover S, Aggarwal M, Dutt A, Chakrabarti S, Avasthi A, Kulhara P, et al. (2012). Prevalence of metabolic syndrome in patients with schizophrenia in India. Psychiat Res [Epub ahead of print].
20. Grundy SM (2005). Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Arterioscler Thromb Vasc Biol 25:2243-2244.
21. Hagg S, Lindblom Y, Mjorndal T, Adolfsson R (2006). High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 21:93-98.
22. Hayward P, David AS, Green N, Rabe-Hesketh S, Haworth E, Thompson N, et al. (2009). Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial. Clin Schizophr Relat Psychoses 3:127-132.
23. Hodgson R, Adeyemo O (2004). Physical examination performed by psychiatrists. Int J Psychiatry Clin Pract 8:57-60.
24. Holt R, Abdelrahman T, Hirsch M, Dhesi Z, George T, Blincoe T, et al. (2010). The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness. J Psychopharmacol 24:867-873.
25. Howes OD, Bhatnagar A, Gaughran FP, Amiel SA, Murray RM, Pilowsky LS (2004). A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiatry 161: 361-363.
26. Kahn R, Buse J, Ferrannini E, Stern M (2005). The metabolic syndrome: time for a critical appraisal. Diabetes care 28:2289-2304.
27. Kang SH, Kim KH, Kang GY, Lee KH, Kim KK, Soh M, et al. (2011). Cross-sectional prevalence of metabolic syndrome in Korean patients with schizophrenia. Schizophr Res 128:179-181.
28. Keane S, Lane A, Larkin T, Clarke M (2009). Management of clozapine-related hepatotoxicity. J Clin Psychopharmacol 29:606-607.
29. Kim HK, Kim CH, Park JY, Lee KU (2009). Lower waist-circumference cutoff point for the assessment of cardiometabolic risk in Koreans. Diabetes Res Clin Pract 85:35-39.
30. Kim J, Jo I (2009). Relationship between body mass index and alanine aminotransferase concentration in non-diabetic Korean adults. Eur J Clin Nutr 64:169-175.
31. Krakowski M, Czobor P, Citrome L (2009). Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophr Res 110 (1-3):95-102.
32. Lamberti JS, Olson D, Crilly JF, Olivares T, Williams GC, Tu X, et al. (2006). Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 163:1273-1276.
33. Lee NY, Kim SH, Jung DC, Kim EY, Yu HY, Sung KH, et al. (2011). The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving monotherapies with aripiprazole, olanzapine or risperidone. Prog Neuro-psychopharmacol Biol Psychiatry 35:1273-1278.
34. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80:19-32.
35. Meyer J, Koro CE, L'Italien GJ (2005). The metabolic syndrome and schizophrenia: a review [Review]. Int Rev Psychiatr 17:173-180.
36. Meyer JM, Stahl SM (2009). The metabolic syndrome and schizophrenia [Review]. Acta Psychiatr Scand 119:4-14.
37. Meyer JM, Rosenblatt LC, Kim E, Baker RA, Whitehead R (2009). The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. J Clin Psychiatry 70:318-325.
38. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M (2011). Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr Bull [Epub ahead of print].
39. Morgan D, Sargeant M, Chukwuma J, Hughes G (2008). Audit of metabolic syndrome in adults prescribed clozapine in community and long-stay in-patient populations. Psychiatr Bull 32:174-177.
40. Newcomer JW (2007). Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 68 (Suppl 1): 20-27.
41. Nyamdorj R, Qiao Q, Tuomilehto J, Gao W, Nakagami T, Hammar N, et al. (2007). Prevalence of the metabolic syndrome in populations of Asian origin comparison of the IDF definition with the NCEP definition. Diabetes Res Clin Pract 76:57-67.
42. Oh HJ, Kim TH, Sohn YW, Kim YS, Oh YR, Cho EY, et al. (2011). Association of serum alanine aminotransferase and g-glutamyltransferase levels within the reference range with metabolic syndrome and nonalcoholic fatty liver disease. Korean J Hepatol 17:27-36.
43. Oh JY, Sung YA, Lee HJ, Chung HW, Park H (2009). Optimal waist circumference for prediction of metabolic syndrome in young Korean women with polycystic ovary syndrome. Obesity 18:593-597.
44. Papakostas GI (2007). Limitations of contemporary antidepressants: tolerability. J Clin Psychiatry 68:11-17.
45. Qiao Q (2005). Comparison of three different definitions for the metabolic syndrome in non-diabetic Europeans. Br J Diab Vasc Dis 5:161-168.
46. Rejas J, Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M (2008). Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: a corollary from the CLAMORS study. Schizophr Res 99 (1-3):23-28.
47. Schindhelm R, Dekker J, Nijpels G, Stehouwer C, Bouter L, Heine R, et al. (2007). Alanine aminotransferase and the 6 year risk of the metabolic syndrome in Caucasian men and women: the Hoorn Study. Diabetic Med 24:430-435.
48. Schorr SG, Slooff CJ, Bruggeman R, Taxis K (2009). The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year. J Psychiatr Res 43:1106-1111.
49. Seo J, Kim B, Cho H, Kim H, Park J, Baik S, et al. (2009). The cutoff values of visceral fat area and waist circumference for identifying subjects at risk for metabolic syndrome in elderly Korean: Ansan Geriatric (AGE) cohort study. BMC Public Health 9:443.
50. Shi L, Ascher-Svanum H, Chiang YJ, Zhao Y, Fonseca V, Winstead D (2009). Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration. BMC Psychiatry 9:80.
51. Subramaniam M, Ng C, Chong SA, Mahendran R, Lambert T, Pek E, et al. (2007). Metabolic differences between Asian and Caucasian patients on clozapine treatment. Hum Psychopharmacol 22:217-222.
52. Sugawara N, Yasui-Furukori N, Sato Y, Umeda T, Kishida I, Yamashita H, et al. (2010). Prevalence of metabolic syndrome among patients with schizophrenia in Japan. Schizophr Res 123 (2-3):244-250.
53. Sull JW, Yun JE, Lee SY, Ohrr H, Jee SH, Guallar E, et al. (2009). Body mass index and serum aminotransferase levels in Korean men and women. J Clin Gastroenterol 43:869-875.
54. Sung KC, Kim BJ, Kim BS, Lee WY, Park JB, Wilson AM (2009). A comparison of the prevalence of the MS and its complications using three proposed definitions in Korean subjects. Am J Cardiol 103:1732-1735.
55. Suzuki A, Angulo P, Lymp J St, Sauver J, Muto A, Okada T, et al. (2005). Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 41:64-71.
56. Youn H, Lee HJ, Lee NY, Yu HY, Kim YS, Ahn YM (2010). The association of serum alanine aminotransferase and metabolic syndrome in patients with bipolar disorder. J Korean Soc Depress Bipolar Disord 8:126-132.